Voyager Therapeutics stock jumps on 2nd Parkinson's deal

Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.